Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by The Medicines Company of $150 million aggregate principal amount of 3.50% convertible senior notes due 2024.
The Medicines Company is a biopharmaceutical company focused on inclisiran, an investigational agent which is potentially a first-in-class lipid-lowering drug, to reduce LDLcholesterol in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associate Young-Min Cho. The Davis Polk equity derivatives team included partner John M. Brandow and associate Chaoshun (Jeff) Zuo. Partner David R. Bauer and associate Yifu Chen provided intellectual property and technology advice. Partner Michael Farber and associate Daniel L. Jose provided tax advice. The environmental team included counsel Betty Moy Huber. All members of the Davis Polk team are based in the New York office.